Silexion Therapeutics Corp (SLXN)

In the past six months, Silexion Therapeutics Corp. has experienced several events impacting its stock price. On April 28, 2026, they announced the successful submission of a Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204. On March 24, 2026, they received approval from the Israeli Ministry of Health to initiate the Phase 2/3 clinical trial of SIL204. On March 17, 2026, the company reported its Fourth Quarter and Full Year 2025 Financial Results and provided a business update. On March 5, 2026, the company urged shareholders to vote ahead of a March 16 Extraordinary General Meeting. On January 6, 2026, Silexion Therapeutics Corp announced plans to initiate a Phase 2/3 clinical trial for SIL204. As of May 1, 2026, Silexion Therapeutics' stock price was $0.58, with a market capitalization of $2.44 million.

Information regarding demand seasonality for Silexion Therapeutics Corp.'s products and services was not found in the provided search results. Demand for its potential future products would likely be driven by medical need and clinical efficacy rather than typical seasonal patterns.

Silexion Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on RNAi therapies for cancers driven by KRAS mutations. Their technology targets oncogenes at the genetic level, differentiating from small molecule KRAS inhibitors. SIL204, their lead product, is in Phase 2/3 clinical trial for pancreatic cancer. SiG12D-LODER has completed preclinical and Phase I trials, showing efficacy in Phase 2 for pancreatic cancer. Prostate-LODER and GBM-LODER are in preclinical studies for prostate cancer and Glioblastoma Multiforme, respectively. Silexion collaborates with Evonik for advanced siRNA formulation development.

Silexion Therapeutics Corp. is headquartered in Jerusalem, Israel, with executive offices in Ramat Gan, Israel, and is incorporated in the Cayman Islands. The company is expanding globally through clinical trials, having received approval from the Israeli Ministry of Health and submitting a Clinical Trial Application to Germany's BfArM for SIL204. A global Phase 2/3 study is planned to start in the second quarter of 2026, involving oncology centers in Germany, other EU states, and Israel.

Information specifically detailing Silexion Therapeutics Corp.'s brand reputation or events affecting it in the past year was not found in the provided search results. The company's focus appears to be on scientific and clinical advancements in oncology.

Information regarding major institutional and individual owners of Silexion Therapeutics Corp. was not found in the provided search results.